The Latest Breaking News from AnaptysBio

A Relative Strength Rating upgrade for AnaptysBio shows improving technical performance. Will it continue?

AnaptysBio shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 69 to 81.

Upgrades

Upgrades See all analyst ratings upgrades.

Benzinga Pro data, AnaptysBio (NASDAQ:ANAB) reported Q1 sales of $970.00 thousand. Earnings fell to a loss of $36.26 million, resulting in a 11.42% decrease from last quarter.

AnaptysBio Inc (NASDAQ:ANAB) announced topline data from a Phase 1 trial of ANB032, an anti-BTLA agonist antibody.  Topline data demonstrated favorable safety, tolerability, and rapid and sustained pharmacokinetics and pharmacodynamic profile, supporting the advancement of ANB032 into subsequent patient trials. ANB032 was generally well-tolerated, and no dose-limiting toxicities were observed. The Company said…

AnaptysBio Inc's (NASDAQ: ANAB) Phase 2 ACORN trial of imsidolimab for moderate-to-severe acne 

AnaptysBio (NASDAQ:ANAB) brought in sales totaling $1.01 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 388.12%, resulting in a loss of $32.54 million.

  AnaptysBio (NASDAQ:ANAB) reported its Q4 earnings results on Monday, March 7, 2022 at 09:00 AM. Here's what investors need to know about the announcement. Earnings AnaptysBio reported an EPS of $-1.18.